Cure Pharmaceutical Holdings has signed a definitive agreement to acquire Sera Labs Inc. The closing is anticipated to occur in early October.   The transaction consists of an up-front payment of $20 million, of which $1 million was paid in cash and $19 million has been allocated in Cure stock at a valuation of $2.75 per share. The transaction also includes an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth, and earn out incentives of...